Clinical Trial

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-28; most recent amendment 2026-06-25.
Status change: Not Yet Recruiting → Recruiting 2026-02-12
Trial Details
NCT Number NCT07149363
Lead Sponsor Alliance Foundation Trials, LLC.
Collaborators: AstraZeneca
Conditions Small Cell Lung Cancer (SCLC)
Enrollment 65 participants
Start Date 2026-02-12
Primary Completion 2029-02 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-26